Drugs for Angiodysplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 18)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Somatostatin |
Approved, Investigational |
Phase 2, Phase 3 |
|
51110-01-1, 38916-34-6 |
53481605 |
Synonyms:
(5S,8R,14R,17R,20R,23R,26R,29R,32R,35R)-38-[(2-{[(2R)-2-amino-1-hydroxypropylidene]amino}-1-hydroxyethylidene)amino]-20,35-bis(4-aminobutyl)-14,26,29-tribenzyl-7,10,13,16,19,22,25,28,31,34,37-undecahydroxy-32-[(C-hydroxycarbonimidoyl)methyl]-11-(1-hydroxyethyl)-17-[(1S)-1-hydroxyethyl]-8-(hydroxymethyl)-23-[(1H-indol-3-yl)methyl]-1,2-dithia-6,9,12,15,18,21,24,27,30,33,36-undecaazacyclononatriaconta-6,9,12,15,18,21,24,27,30,33,36-undecaene-5-carboxylate
Growth hormone-inhibiting hormone (ghih)
Somatostatin
Somatostatina
Somatostatine
|
Somatostatinum
Somatotropin release-inhibiting factor (srif)
Somatotropin release-inhibiting hormone
Synthetic growth hormone release-inhibiting hormone
Synthetic somatostatin-14
|
|
2 |
|
Octreotide |
Approved, Investigational |
Phase 2, Phase 3 |
|
83150-76-9 |
383414 6400441 |
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
(4R,7S,10S,13R,16S,19R)-19-{[(2R)-2-amino-1-hydroxy-3-phenylpropylidene]amino}-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
Compound 201 995
Compound 201995
Compound 201-995
D00442
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
DRG-0115
HMS2090C09
HS-2020
L000453
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
|
Longastatin
LS-177735
LS-187135
NCGC00181796-01
nchembio.184-comp3
NCI60_025753
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide [USAN:INN:BAN]
Octreotide acetate
Octreotide acetate salt
Octreotide Acetate Salt
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
Sandostatin
Sandostatine
Sandoz 201 995
Sandoz 201995
Sandoz 201-995
SM 201-995
SMS 201-995
SMS-201-995
UNII-RWM8CCW8GP
zacycloicosane-4-carboxamide acetate
|
|
3 |
|
Antineoplastic Agents, Hormonal |
|
Phase 2, Phase 3 |
|
|
|
4 |
|
Gastrointestinal Agents |
|
Phase 2, Phase 3 |
|
|
|
5 |
|
Pasireotide |
Approved |
Phase 2 |
|
396091-73-9 |
9941444 |
Synonyms:
cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-)
Pasireotida
Pasireotide
|
|
|
6 |
|
Iron |
Approved |
Phase 2 |
|
7439-89-6 |
23925 29936 |
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
Ancor B
Ancor en 80/150
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
ATW 230
ATW 432
C00023
C3518_SIAL
C3518_SIGMA
Carbonyl iron
CCRIS 1580
CHEBI:18248
CID23925
Copy Powder CS 105-175
D007501
DB01592
Diseases (animal), iron overload
Diseases, iron overload
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Ed-In-Sol
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
Eisen
Electrolytic iron
F 60 (metal)
|
Fe
FE
FE (III) ion
Fe(3+)
Fe(III)
Fe1+
Fe-40
fer
Feronate
Ferretts
Ferric ion
Ferric iron
Ferro-Caps
Ferro-Time
ferrous iron
Ferrousal
Ferrovac E
Ferrum
Ferrum metallicum
FT 3 (element)
GS 6
Hemocyte
HF 2 (element)
hierro
Hierro
HL (iron)
Hoeganaes ATW 230
Hoeganaes EH
HQ (metal)
HS (iron)
HS 4849
HSDB 604
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(3+)
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (fe(3+))
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, reduced
LOHA
LS-3196
MolPort-003-925-001
NC 100
PZh1M1
PZh-1M3
PZh-2
PZh2M
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
Reduced iron
Remko
Siderol
SUY-B 2
UNII-E1UOL152H7
Vitedyn-Slo
Yieronia
|
|
7 |
|
Ferrous succinate |
Approved |
Phase 2 |
|
10030-90-7 |
|
Synonyms:
|
8 |
|
Hormone Antagonists |
|
Phase 2 |
|
|
|
9 |
|
Hormones |
|
Phase 2 |
|
|
|
10 |
|
Angiogenesis Inhibitors |
|
Phase 2 |
|
|
|
11 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
12 |
|
Immunosuppressive Agents |
|
Phase 2 |
|
|
|
13 |
|
Hematinics |
|
Phase 2 |
|
|
|
14 |
|
Anti-Infective Agents |
|
Phase 2 |
|
|
|
15 |
|
Anti-Bacterial Agents |
|
Phase 2 |
|
|
|
16 |
|
Pomalidomide |
Approved |
Phase 1 |
|
19171-19-8 |
|
Synonyms:
|
17 |
|
Infliximab |
Approved |
|
|
170277-31-3 |
|
Synonyms:
Ig gamma-1 chain C region
Infliximab (genetical recombination)
Infliximab-abda
Infliximab-axxq
|
Infliximab-dyyb
Infliximab-qbtx
Remicade
|
|
18 |
|
Hemostatics |
|
|
|
|
|
Interventional clinical trials:
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Multicenter, Randomized, Open-label Clinical Trial Assessing the Efficacy of Octreotide in Decreasing Blood and Iron Requirements in Patients With Refractory Anaemia Due to Angiodysplasias |
Unknown status |
NCT02384122 |
Phase 2, Phase 3 |
Octreotide |
2 |
A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRXâ„¢ Anorectal Wand |
Unknown status |
NCT03302858 |
Phase 2 |
|
3 |
Randomized Phase II Trial Evaluating the Efficiency of Pasireotide for the Treatment of Gastrointestinal Angiodysplasia in Endoscopic Treatment Failure |
Completed |
NCT02622906 |
Phase 2 |
Pasireotide;Placebo |
4 |
Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation : An Open-label, Randomized, Parallel Controlled Study |
Completed |
NCT00964496 |
Phase 2 |
Thalidomide;Iron |
5 |
A Phase I Single Arm Study to Assess the Safety and Efficacy of Pomalidomide in Patients With Bleeding Due to Hereditary Hemorrhagic Telangiectasia and Refractory Angiodysplasia |
Completed |
NCT02287558 |
Phase 1 |
Pomalidomide |
6 |
A Randomized Controlled Trial of Capsule Endoscopy vs Standard Care in Patients With Iron Deficiency Anemia With Suspected Obscure / Occult Gastrointestinal Bleeding |
Completed |
NCT00694954 |
|
|
7 |
Prospective Comparison of the Diagnostic Yield of Small Bowel Pillcam SB2 and Capsocam Capsule in Patients With Obscure Digestive Bleedings |
Completed |
NCT01820182 |
|
|
8 |
A Prospective Observational Cohort Study of Hemospray for Lower Gastrointestinal Hemorrhage (APPROACH LGI) |
Completed |
NCT02099435 |
|
|
9 |
Treatment of Ex-vivo Small Bowel Mucosa With a Dedicated Radiofrequency Ablation (SB-RFA) Catheter. |
Withdrawn |
NCT03320395 |
|
|
Cochrane evidence based reviews: angiodysplasia
|